Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone Long-acting Injectable in Recent Onset Psychosis
NCT00216580Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2004
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of risperidone in schizophrenia, schizophreniform disorder, schizoaffective disorder, sponsored by Janssen Pharmaceutical. Started Feb 2004; status: completed.
02
Drugs
risperidone
03
Conditions
schizophreniaschizophreniform disorderschizoaffective disorder
Beyond the preview
Go deeper on NCT00216580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00216580.